mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. - Test2 - elhamkhani - TriplyDB

mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors.

mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors.

http://www.wikidata.org/entity/Q27851707

about

Sirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular Effects Toward rapamycin analog (rapalog)-based precision cancer therapy CIViC database Sustained proliferation in cancer: Mechanisms and novel therapeutic targets Detection of rapalog-mediated therapeutic response in renal cancer xenografts using ⁶⁴Cu-bevacizumab immunoPET Loss of 4E-BP1 function induces EMT and promotes cancer cell migration and invasion via cap-dependent translational activation of snail.Selective anti-cancer agents as anti-aging drugs Efficacy and safety of a mammalian target of rapamycin inhibitor in pediatric patients with tuberous sclerosis complex: A systematic review and meta-analysis Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma Cytoplasmic Accumulation of Heterogeneous Nuclear Ribonucleoprotein K Strongly Promotes Tumor Invasion in Renal Cell Carcinoma Cells.AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation.4E-BP1 participates in maintaining spindle integrity and genomic stability via interacting with PLK1.eIF4E binding protein 1 expression is associated with clinical survival outcomes in colorectal cancer PP2AC Level Determines Differential Programming of p38-TSC-mTOR Signaling and Therapeutic Response to p38-Targeted Therapy in Colorectal Cancer.PAT4 levels control amino-acid sensitivity of rapamycin-resistant mTORC1 from the Golgi and affect clinical outcome in colorectal cancer Identification of a Non-Gatekeeper Hot Spot for Drug-Resistant Mutations in mTOR Kinase.The Enigma of Rapamycin Dosage.4E-BP1, a multifactor regulated multifunctional protein Chemopreventive Effect of Dietary Glutamineon Colitis-Associated Colorectal Cancer Is Associated with Modulation of the DEPTOR/mTOR Signaling Pathway.Rapamycin extends life- and health span because it slows aging.The impact of metformin use on recurrence and cancer-specific survival in clinically localized high-risk renal cell carcinoma CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion.mTOR signal transduction pathways contribute to TN-C FNIII A1 overexpression by mechanical stress in osteosarcoma cells mTOR pathway in colorectal cancer: an update.The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials Multiplatform-based molecular subtypes of non-small-cell lung cancer.Targeting mTOR network in colorectal cancer therapy K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.4E-BP2 hardwires lymphocytes for rapamycin sensitivity.Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1.New insights into 4E-BP1-regulated translation in cancer progression and metastasis.The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy.mTOR kinase-dependent, but raptor-independent regulation of downstream signaling is important for cell cycle exit and myogenic differentiation.Yin and yang of 4E-BP1 in cancer.Expression level of phosphorylated-4E-binding protein 1 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors.Glycogen synthase kinase-3β positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E-binding protein 1.Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition.RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition.Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome–like acute B-cell lymphoblastic leukemia.

P2860

Q26749011-6C4C3932-2D71-4E68-A47E-6428FCC6F5B8 Q26795606-DD7DA799-1E5C-4F99-B247-A633C33C1107 Q27612411-76C7DFA1-AF28-4451-A2C8-DFAFB04C53A8 Q28396388-19E88055-8C91-4C44-96AF-D732C8D2D55D Q28487987-DAAF0754-70A3-4ABC-B136-65B9D58B389F Q34227565-4C948B2C-8861-4AE0-8E78-1F48ABDC5A5F Q34392470-7FCE96DD-23A0-4562-9D7C-349323322F8F Q34795499-E864575B-A362-4870-8D21-8185FB93378C Q34977124-DE065A13-4474-438B-8309-832AB26E7ED6 Q35880529-5C59A63E-5E41-4635-AC04-B3DCBFB53114 Q35987253-30D24B91-F1FF-4BF9-A065-958AC5333B98 Q36156993-3C86EB64-A85E-4666-AC05-46E774A9B786 Q36304185-C8619DFD-B521-4B1F-80CA-A6620F0A80A6 Q36414386-BA2922D2-DD86-41F1-B566-B7394007614C Q36437685-179C5E4B-A1EA-461C-8796-EF828BE67876 Q36442548-3780388E-F621-4F93-AF8F-AC1802DD700F Q36600668-8207E71E-DDBC-41D9-8FA5-75DA466EE4C2 Q36664900-8E0E7F31-9A55-4EDA-9A2D-D0B78B9EA695 Q36838384-7FC2267E-BB06-4082-A0EB-29BEB13A93EC Q36941743-9557E663-082C-42CF-840F-BAC64DD0378F Q37228766-78E0C874-DB80-4D19-8D8E-8FBDB7CB0C5C Q37342956-83893375-D0DD-4B19-BBE0-B3050C36DEAC Q37420058-5BD372C2-AC2F-4907-AE21-680279DFFA4A Q37604821-3CD05347-E0CA-46E9-BFA9-29B109177510 Q37649634-FF9A3FA8-8E2A-4B23-85FD-D5CC4FE85ADA Q37690538-CFFE1B67-6524-4E9F-BF4B-5D8C9D76A2F7 Q37691784-E7F7395F-7B12-4571-A1C5-5A66FC69B2C0 Q37708005-A7EA4DDD-98BF-43B5-9BA0-FE833ECD67B8 Q38678966-E6A50C16-DD5C-4305-B374-9D0094D615C9 Q38849288-3B068A21-5B10-45C8-9EEF-A3D0BB5F31EB Q39067602-D58AEDD7-A570-4575-930D-1B0C711EAA66 Q40948168-A18A12F4-3E69-4A4B-80D6-14FB9F793EBD Q41036251-87D6DD3C-8899-4FD4-B5A6-25F5EE8A295E Q41716371-CF8F56E5-0A75-4348-B70D-5A3B9B168967 Q41896109-350D3EB1-6100-4F20-8806-2F838A1E8302 Q44392784-0C5D3ACB-3CE8-489A-BE7C-E04F4314DFB2 Q45735011-182D046C-82DD-40EC-9D01-E5A9B389F359 Q48011517-8CD05D72-5EB4-4EAE-9E20-BB38F903C75A Q48123819-8E60E45C-35E8-4DB5-A94C-55302C2ED197 Q50308754-72AE8FDA-3245-442B-B111-D0BD96942A46

P2860

mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors.

http://www.wikidata.org/entity/Q27851707

description

2012 nî lūn-bûn

@nan

2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

mTOR-independent 4E-BP1 phosph ...... nce to mTOR kinase inhibitors.

@ast

mTOR-independent 4E-BP1 phosph ...... nce to mTOR kinase inhibitors.

@en

mTOR-independent 4E-BP1 phosph ...... nce to mTOR kinase inhibitors.

@nl

type

label

mTOR-independent 4E-BP1 phosph ...... nce to mTOR kinase inhibitors.

@ast

mTOR-independent 4E-BP1 phosph ...... nce to mTOR kinase inhibitors.

@en

mTOR-independent 4E-BP1 phosph ...... nce to mTOR kinase inhibitors.

@nl

altLabel

mTOR-independent 4E-BP1 phosph ...... ance to mTOR kinase inhibitors

@en

prefLabel

mTOR-independent 4E-BP1 phosph ...... nce to mTOR kinase inhibitors.

@ast

mTOR-independent 4E-BP1 phosph ...... nce to mTOR kinase inhibitors.

@en

mTOR-independent 4E-BP1 phosph ...... nce to mTOR kinase inhibitors.

@nl

P1433

Q27851707-478DCC8D-4F5A-4195-83B7-88EBE911233D

P1476

Q27851707-11F15824-5BE5-46BE-AA47-E06660E869F7

P2093

Q27851707-08895B8F-D3F4-4AFC-92E0-F97BF5A0584E

Q27851707-C2B11BAF-C88E-4540-AB87-BD0814BACE22

P2860

Q27851707-0463573A-D4AC-4CAA-A50C-04EE432AA60F

Q27851707-05CD7A6D-793E-4D64-8BD1-5B7A989F4A8B

Q27851707-083EB513-FDC3-4DB7-9A95-F416A71D305D

Q27851707-0DC4E87B-387C-429E-8295-A1E23C07FD14

Q27851707-133501F8-78C8-4464-9896-AE834D8DC6AC

Q27851707-19AC2946-3678-4505-A662-A0FAF897DE47

Q27851707-241F1CFE-0534-44BE-AF18-B121224EC9F5

Q27851707-2DEA276C-902A-463E-8BB5-83B939B83216

Q27851707-2EBF0C07-96F5-443B-B7C9-BDEC06F29196

Q27851707-3770E7E5-1AB2-4F19-80F1-7559AFBADFA5

P304

Q27851707-0BD8EE03-245F-4896-980D-D1CABBB39C21

P31

Q27851707-C64A0224-5DD1-49B0-913E-E89F7B5984FD

P3181

Q27851707-7EDEFE56-C31A-4A4C-86FD-AEAA8DD958BF

P356

Q27851707-4643900C-183F-4A60-B0DB-46F1129CBAE1

P407

Q27851707-79DE2A65-5E80-428F-B57D-1A56902B3D80

P433

Q27851707-4DF7ACB7-8AB3-44C1-A11A-C5DB9FDC4004

P478

Q27851707-B2E1C7C6-0676-46BB-BA9B-CB61920249D3

P577

Q27851707-25D8D8B0-EDBA-4279-9C45-DFE7A4397B40

P5875

Q27851707-1D2BEB6C-CF0A-4FCC-A2F7-407A7294EB17

P698

Q27851707-D1E367BC-24E1-4ADB-8AE3-83C2C1702F36

P921

Q27851707-07F600E2-0D4B-418F-AD25-BD1DA12088C9

Q27851707-20E5C040-9A8A-4352-A705-D14985DBA5EF

P932

Q27851707-A08A4619-A3ED-40D5-9B73-1627892FF3B5

P3181

P356

P1433

P1476

mTOR-independent 4E-BP1 phosph ...... nce to mTOR kinase inhibitors.

@en

P2093

X F Steven Zheng

http://www.w3.org/2001/XMLSchema#string

Yanjie Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control

The FKBP12-rapamycin-associated protein (FRAP) is a CLIP-170 kinase

Targeting mTOR for the treatment of AML. New agents and new directions

Targeting the mTOR kinase domain: the second generation of mTOR inhibitors

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

Global cancer statistics, 2002

P304

594-603

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1632772

http://www.w3.org/2001/XMLSchema#string

P356

10.4161/CC.11.3.19096

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221763691

http://www.w3.org/2001/XMLSchema#string

P698

22262166

http://www.w3.org/2001/XMLSchema#string

P921

phosphorylation

P932

3315097

http://www.w3.org/2001/XMLSchema#string